Biogen Idec reports positive MS drug trial data

Biogen Idec has reported positive new clinical data showcasing the safety and efficacy of its new multiple sclerosis (MS) drug BG-12.

Detailed results from Confirm – the second phase III clinical trial of oral BG-12 in people with relapsing-remitting MS – have been presented this week, during which it showed efficacy across a variety of clinical and radiological outcome measures.

The drug significantly reduced annualised relapse rates compared to placebo over two years, while also demonstrating favourable safety and tolerability profiles.

These new findings tally with the positive results from the earlier Define trial and will be used to support applications for US and European regulatory approval of the drug.

Dr Douglas Williams, Biogen Idec's executive vice-president of research and development, said: "If approved by regulators, we believe BG-12 could be an important new oral therapeutic option for MS patients."

BG-12 is one of a number of neurology treatments showcased by Biogen Idec at this week's American Academy of Neurology annual meeting, with others including Tysabri, Avonex and dexpramipexole.